BioNTech SE (NASDAQ:BNTX) is included among the 10 Best Global Stocks to Buy According to Wall Street Analysts. BioNTech SE ...
Zacks Investment Research on MSN
BioNTech (BNTX) surges 6.1%: Is this an indication of further gains?
BioNTech SE Sponsored ADR (BNTX) shares ended the last trading session 6.1% higher at $111.6. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...
View BioNTech SE Sponsored ADR BNTX stock quote prices, financial information, real-time forecasts, and company news from CNN.
BioNTech’s fair value estimate has been trimmed from $139.51 to $131.39, a modest cut of about 6% that reflects the latest model inputs. This shift comes as analysts reassess the story around ...
BioNTech SE BNTX was down sharply on Tuesday after issuing weaker‑than‑expected 2026 revenue guidance as Covid vaccine sales normalize and outlining a capital‑intensive pivot toward oncology. The ...
We came across a bullish thesis on BioNTech SE on Memyselfandi007’s Substack. In this article, we will summarize the bulls’ thesis on BNTX. BioNTech SE’s share was trading at $103.80 as of March 4th.
Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.
BioNTech SE – ADR (NASDAQ: BNTX) reported upbeat fourth-quarter financial results and issued FY26 sales guidance below estimates on Tuesday. BioNTech reported quarterly losses of 38 cents per share ...
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results